Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of chicken Newcastle disease and h9 subtype avian influenza double combination vaccine

A dual vaccine, avian influenza virus technology, applied in the field of chicken Newcastle disease and H9 subtype avian influenza dual vaccine, can solve the problems of affecting the vaccine control effect, low antibody level, and poor clinical application effect, etc. Good originality, small immune dose, and long-lasting effect

Active Publication Date: 2017-12-05
YEBIO BIOENG OF QINGDAO
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The existing avian influenza (H9 subtype) vaccine has been widely used clinically, but there are problems with low antibody level and antibody uniformity, which affect the prevention and control effect of the vaccine
Moreover, the strains used for vaccine production are the popular strains many years ago. With the passage of time and environmental changes, the clinical epidemic strains of avian influenza (H9 subtype) have undergone antigenic variation. Antibodies, unable to provide complete immune protection against epidemic strains, and the clinical application effect is not good

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of chicken Newcastle disease and h9 subtype avian influenza double combination vaccine
  • A kind of chicken Newcastle disease and h9 subtype avian influenza double combination vaccine
  • A kind of chicken Newcastle disease and h9 subtype avian influenza double combination vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Embodiment 1, the screening of antigenic strain (H9 subtype avian influenza virus QDY strain) for making seedlings

[0016] In 2013, from the infected chickens that had been vaccinated with the H9 subtype avian influenza virus vaccine in Chengyang, Shandong, aseptically collected heart, spleen and other organs, larynx, and cloacal swabs of the affected chickens, and put them in a sterile plate under sterile conditions. After crushing, add physiological saline containing 4000 units / ml double antibody at a ratio of 1:5, and freeze and thaw repeatedly at -20°C for 3 times. Put the cotton swab directly into the physiological saline containing 10,000 units of double antibody, act for 4 hours at 2-8°C, centrifuge the viscera and cotton swab at 3500 rpm for 10 minutes, take the supernatant, mix and inoculate 10-day-old SPF chicken embryo 5 Pieces, 0.2ml / piece. Chicken embryos were incubated at 37°C, inspected once a day in the morning and evening, and the dead embryos were ta...

Embodiment 2

[0020] Embodiment 2: the preparation and inspection of Newcastle disease, avian influenza (H9 subtype) dual inactivated vaccine

[0021] 1. Preparation of Antigen Solution for Seedling Production

[0022] 1.1 Preparation of avian influenza (H9 subtype) antigen solution

[0023] 1.1.1 Propagation of avian influenza (subtype H9) virus Dilute the virus seed (QDY strain) 20,000 times with sterilized normal saline, inoculate 10-11-day-old SPF chicken embryos through the allantoic cavity, 0.2ml per embryo, inoculate Finally, seal the pinholes and continue to incubate at 36-37°C without turning the embryos. The embryos were photographed once a day, and the chicken embryos that died 48 hours ago were discarded. After that, take out the embryos every 4 to 6 hours, and take out the dead chicken embryos at any time until 72 hours, regardless of whether they are dead or not, take them out, and separate the dead chicken embryos from the still alive chicken embryos according to the embryo...

Embodiment 3

[0036] One, the preparation of inactivated vaccine: the semi-finished product antigen after passing the inspection is carried out vaccine preparation (in the following preparation, each liquid component is calculated by volume ratio).

[0037]1. Oil phase preparation Take 95 parts of veterinary white oil and 1 part of aluminum stearate, put it in the oil phase preparation tank and heat it to 80°C, then add 805 parts of Siben-805, and keep it for 30 minutes when the temperature reaches 115°C , and set aside after cooling.

[0038] 2. Preparation of water phase Mix inactivated chicken Newcastle disease virus embryo fluid and H9 subtype avian influenza virus embryo fluid in an appropriate ratio, so that the amount of chicken Newcastle disease virus in each 0.1ml water phase is not less than 10 8.0 EID 50 , H9 subtype avian influenza virus content is not less than 10 7.5 EID 50 . Take 4 parts of sterilized Tween-80, add 96 parts of mixed antigen solution, and stir in the water...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention aims at providing a new castle disease and H9 subtype bird flu bivalent vaccine. The new castle disease and H9 subtype bird flu bivalent vaccine contains antigens and adjuvant. The antigens are inactivated H9 subtype bird flu viruses and new castle disease viruses. The H9 subtype bird flu viruses are QDY strains, and the preservation number of the H9 subtype bird flu viruses is CCTCC v201517. The QDY strains of the H9 subtype bird flu viruses and a Lasota strain of the new castle disease viruses are inoculated to chick embryos respectively, and then virus liquid is collected; the virus liquid and the oil adjuvant are mixed and emulsified into the vaccine after the virus liquid is inactivated through a formaldehyde solution. The new castle disease and bird flu bivalent inactivated vaccine is good in immunogenicity, antibody production is fast after immunity, the produced antibody titer is high, the produced antibody holding time is long, the retention period is long, the immunizing dose is small, the selected adjuvant is easy to inject, and two kinds of diseases can be prevented through one-time injection. The vaccine has the advantages of being efficient and good in safety.

Description

technical field [0001] The invention belongs to the technical field of biological veterinary medicines, and in particular relates to a dual vaccine against Newcastle disease and H9 subtype avian influenza. Background technique [0002] H9 subtype avian influenza is a low-pathogenic disease, but mixed infection with other pathogens, especially Newcastle disease and E. hazards. [0003] The occurrence of low-pathogenicity H9 subtype avian influenza is potential, extremely widespread, persistent and difficult to control, bringing catastrophe to the poultry industry, and equally serious threat to human beings. The existing avian influenza (subtype H9) vaccine has been widely used clinically, but there are problems of low antibody level and antibody uniformity, which affect the prevention and control effect of the vaccine. Moreover, the strains used for vaccine production are the popular strains many years ago. With the passage of time and environmental changes, the clinical ep...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/17A61K39/145A61P31/14A61P31/16A61K39/39
Inventor 刘新文范根成胡潇宫晓李陆梅邹敏王秀丽
Owner YEBIO BIOENG OF QINGDAO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products